| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | 1 | 3 | — | — | — | — | — | — | — | — | — |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 0.74 | 0.06 | 1.49 | 0.23 |
| Receivables | — | — | — | — |
| Inventory | 0.02 | — | — | — |
| Other | 0.02 | 0.02 | 0.05 | 0.02 |
| 0.84 | 0.08 | 1.55 | 0.25 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.14 | 0.84 | 0.42 | 0.90 |
| ST’ Debt | — | — | — | — |
| Other | 0.01 | 0.37 | 0.17 | 0.43 |
| 0.21 | 1.43 | 0.89 | 1.40 |
| 10y | 5y | 3y | |
| Sales | — | — | ‡‡‡‡‡ |
| Cash Flow | — | — | ‡‡‡ |
| Earnings | — | — | ‡‡‡ |
| Book Value | — | — | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.07 | 0.07 | — | — |
—
|
| ’25 | 0.11 | 0.17 | 0.08 | 0.09 |
0.46
|
| ’24 | 0.21 | 0.16 | 0.13 | 0.11 |
0.62
|
| ’23 | 0.10 | 0.14 | 0.25 | 0.24 |
0.73
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.31) | (0.26) | — | — |
—
|
| ’25 | (2.27) | (1.26) | (1.24) | (1.08) |
(5.85)
|
| ’24 | (0.99) | (1.58) | (1.17) | (1.13) |
(4.86)
|
| ’23 | (1.81) | (1.78) | (1.71) | (1.70) |
(7.00)
|
| ’22 | (0.02) | (0.08) | (0.60) | (0.65) |
(1.35)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.31) | (0.26) | — | — |
—
|
| ’25 | (2.27) | (1.26) | (1.24) | (1.08) |
(5.85)
|
| ’24 | (0.99) | (1.51) | (1.17) | (1.13) |
(4.80)
|
| ’23 | (1.81) | (1.78) | (1.71) | (1.70) |
(7.00)
|
| ’22 | (0.02) | (0.08) | (0.60) | (0.69) |
(1.39)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.22) | (0.09) | — | — |
—
|
| ’25 | (1.29) | (0.57) | (0.69) | (0.01) |
(2.17)
|
| ’24 | (1.50) | (1.35) | (0.99) | (1.01) |
(4.84)
|
| ’23 | (0.23) | (2.10) | (1.65) | (1.95) |
(8.55)
|
| ’22 | — | (0.02) | — | (0.04) |
(0.12)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 3.98 | 2.07 | 0.52 | — | — | — |
Low Price
|
| — | — | — | — | — | — | — | 65.55 | 16.80 | 6.15 | — | — | — |
High Price
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Employees
|
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | 0.01 | 0.73 | 0.62 | 0.46 | — | — | — |
Revenue
|
| — | — | — | — | — | — | 55.06% | 58.99% | 61.70% | 54.91% | — | — | — |
Gross Margin
|
| — | — | — | — | — | ‡‡‡ | (2.00) | (9.21) | (8.71) | (20.64) | — | — | — |
EBT
|
| — | — | — | — | — | ‡‡‡ | (22,450.56%) | (1,259.38%) | (1,413.74%) | (4,527.08%) | — | — | — |
EBT Margin
|
| — | — | — | — | — | ‡‡‡ | (2.00) | (9.21) | (8.71) | (20.64) | — | — | — |
Net Income
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 0.02 | 0.73 | 2.96 | — | — | — |
Depreciation
|
| — | — | — | — | — | ‡‡‡ | 0.01 | 0.68 | 0.31 | 0.05 | — | — | — |
Revenue/Sh
|
| — | — | — | — | — | ‡‡‡ | (0.12) | (8.55) | (4.84) | (2.17) | — | — | — |
Earnings/Sh
|
| — | — | — | — | — | ‡‡‡ | (1.87) | (6.51) | (2.46) | (0.58) | — | — | — |
Cash Flow/Sh
|
| — | — | — | — | — | ‡‡‡ | (0.06) | 0.00 | 0.03 | 0.00 | — | — | — |
Capex/Sh
|
| — | — | — | — | — | ‡‡‡ | (1.93) | (6.52) | (2.42) | (0.58) | — | — | — |
Free CF/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | 0.85 | 0.72 | 7.05 | 1.51 | — | — | — |
Book Value/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | 0.72 | 1.07 | 1.98 | 10.07 | — | — | — |
Shares
|
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
PE Ratio
|
| — | — | — | — | — | — | 0.00 | 6.39 | 7.78 | 16.34 | — | — | — |
PS Ratio
|
| — | — | — | — | — | — | 70.38 | 6.03 | 0.34 | 0.49 | — | — | — |
PB Ratio
|
| — | — | — | — | — | — | 0.00 | 5.57 | 7.91 | 13.40 | — | — | — |
EV/Sales
|
| — | — | — | — | — | — | (31.84) | (0.58) | (1.02) | (1.06) | — | — | — |
EV/FCF
|
| — | — | — | — | — | ‡‡‡ | (1.35) | (7.00) | (4.86) | (5.85) | — | — | — |
Op' Cash Flow
|
| — | — | — | — | — | ‡‡‡ | (0.04) | 0.00 | 0.07 | — | — | — | — |
Capex
|
| — | — | — | — | — | ‡‡‡ | (1.39) | (7.00) | (4.80) | (5.85) | — | — | — |
FCF
|
| — | — | — | — | — | ‡‡‡‡‡ | 0.43 | 0.62 | (1.35) | 0.66 | — | — | — |
Working Cap'
|
| — | — | — | — | — | ‡‡‡‡‡ | 0.35 | — | — | — | — | — | — |
Total Debt
|
| — | — | — | — | — | ‡‡‡‡‡ | (0.33) | (0.74) | (0.06) | (1.49) | — | — | — |
Net Debt
|
| — | — | — | — | — | ‡‡‡‡‡ | 0.61 | 0.77 | 13.95 | 15.20 | — | — | — |
Sh' Equity
|
| — | — | — | — | — | ‡‡‡ | (389.53%) | (896.98%) | (106.03%) | (131.23%) | — | — | — |
ROA
|
| — | — | — | — | — | ‡‡‡ | (438.29%) | (16,094.45%) | (35.88%) | (82.19%) | — | — | — |
ROIC
|
| — | — | — | — | — | ‡‡‡ | (669.04%) | (1,326.67%) | (118.29%) | (141.66%) | — | — | — |
ROE
|
Mangoceuticals, Inc. (MGRX) embodies the high-risk volatility of microcap biotechs, with shares plummeting over 99% from 2023 manic highs to sub-dollar levels in early 2026, amid aggressive dilutions, reverse splits, and executives cashing out. While revenue surged dramatically from near-zero in 2022 to $731,500 in 2023 before contracting 16% in 2024—buoyed by post-COVID wellness hype in mango-infused supplements—gross margins offer modest improvement to 61.7%, hinting at pricing power in a crowded nutraceutical market. Yet, this top-line flash masks a skeletal operation with no reported employees and fleeting demand sustainability.
The real peril lies in a profitability black hole: net losses ballooned to $9.2 million in 2023, cash flows burned fiercely (operating cash flow down 420% at its nadir), and returns like ROIC plunged to -161%, eroding book value despite suspicious equity infusions. Valuation multiples swing wildly from overreach to apparent bargains (PB at 0.34x), but negative free cash flow signals ongoing dilution risks, compounded by working capital flipping negative and absent Wall Street coverage.
Insider selling—$174,000 unloaded by the CFO and a director in late 2025—signals waning conviction, presaging further declines amid regulatory scrutiny, competition, and liquidity crunches. In a cautious portfolio, MGRX screams value trap over turnaround; extrapolate the trends, and OTC delisting looms. Dive deeper for the full contrarian breakdown.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.